ライフサイエンスコーパス: bispecific

1 re to a second dose of low-affinity anti-TfR bispecific.

2 e CD5xDR-CR3 or -MUT4 background, leading to bispecific Ab (BsAbs) with a more rigid or flexible stru

3 peripheral blood for adoptive therapy, using bispecific Ab blinatumomab (CD3 x CD19), acting both as

4 ersistent or relapsed MRD, a T cell-engaging bispecific Ab construct induced an 80% MRD response rate

5 ressed CLL patients and, in combination with bispecific Ab, as antitumor immunotherapy.

6 After cross-linking, via a bispecific Ab, redirected regulatory T cells upregulate

7 T4, were designed and tested, and prototypic bispecific Abs directed against CD5 and HLA-DR were prod

8 Bispecific Abs hold great potential for immunotherapy of

9 cific redirection of regulatory T cells with bispecific Abs holds great potential for the treatment o

10 redirecting T cells via the novel humanized bispecific Abs results in a delay of tumor growth in xen

11 To address this problem, we created bispecific Abs that combine the HIV-1 inhibitory activit

12 production of tetravalent IgG1-like chimeric bispecific Abs.

13 nd humanized anti-CD3-anti-PSCA single-chain bispecific Abs.

14 we have generated a full antibody dimer with bispecific activity that retains the activity and stabil

15 ance (SPR) assays that detect ADAs against a bispecific Adnectin drug molecule that consists of an an

16 sion of the immunotoxin approach to generate bispecific agents that may be useful to target complex p

17 e applicable to the generation of additional bispecific agents using drug-like ligands selective for

18 ndogenous biotin interference, make the CD38 bispecific an attractive candidate for clinical translat

19 when both CD19 and CD32b were coengaged by a bispecific anti-CD19xCD32b Ab, both types of stimuli wer

20 in their report from a phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13.

21 We further demonstrate that a bispecific anti-CD70/SIRPalpha antibody outperforms indi

22 Here, we report the development of bispecific anti-Env neutralizing antibodies (biNAbs) wit

23 Chemically programmed bispecific antibodies (biAbs) endow target cell-binding

24 Bispecific antibodies (biAbs) that mediate cytotoxicity

25 e used antibody engineering to develop novel bispecific antibodies (Bis-mAbs) that are cross-reactive

26 ied using PrA-MS and are presented here: (a) bispecific antibodies (bsAb) and (b) glycan engineered a

27 Methods to rapidly generate high quality bispecific antibodies (BsAb) having normal half-lives ar

28 T cell-recruiting bispecific antibodies (bsAb) show promise in hematologic

29 s such as antibody-drug conjugates (ADC) and bispecific antibodies (bsAb), are the fastest growing cl

30 d DNL to generate a novel class of trivalent bispecific antibodies (bsAb), each comprising an anti-CD

31 for the generation of therapeutic human IgG1 bispecific antibodies (bsAb).

32 Bispecific antibodies (bsAbs) and antibody-drug conjugat

33 Bispecific antibodies (bsAbs) are Abs composed of two di

34 Bispecific antibodies (bsAbs) are of significant importa

35 Bispecific antibodies (bsAbs) are one of the most versat

36 Bispecific antibodies (bsAbs) combine the antigen specif

37 Many methods have been developed to produce bispecific antibodies (BsAbs) for industrial application

38 cacy of engaging multiple drug targets using bispecific antibodies (BsAbs) is affected by the relativ

39 g T cells to hematological malignancies with bispecific antibodies (BsAbs) is an attractive strategy.

40 Producing pure and well behaved bispecific antibodies (bsAbs) on a large scale for precl

41 Bispecific antibodies (bsAbs) that lack the immunoglobul

42 The promise of bispecific antibodies (bsAbs) to yield more effective th

43 Four different formats of bispecific antibodies (bsAbs) were generated that consis

44 This results in functionally monovalent, bispecific antibodies (bsAbs) with unknown specificity a

45 Bispecific antibodies (bscAbs), particularly those of th

46 Synergistic bispecific antibodies against HIV exhibit extraordinary

47 We have shown that bispecific antibodies against TfR and beta-secretase (BA

48 ntibody-drug conjugates, conjugate vaccines, bispecific antibodies and cell therapy.

49 These results support this new approach to bispecific antibodies and offer a potential new strategy

50 rved following administration of natural and bispecific antibodies and, more recently, following adop

51 Bispecific antibodies are considered attractive bio-ther

52 These results suggest that IgG-based bispecific antibodies are promising candidates for the p

53 pecificities can dissociate and recombine in bispecific antibodies both in vitro and in vivo.

54 ltaneous engagement of two distinct targets, bispecific antibodies broaden the potential utility of a

55 We show that IgG4 bispecific antibodies can be generated in large quantiti

56 Bispecific antibodies combine two different antigen-bind

57 Here we show that bispecific antibodies contain the binding specificities

58 All 3 bispecific antibodies exhibited identical pharmacokineti

59 tional monoclonal antibodies, knob-into-hole bispecific antibodies face unique challenges in producti

60 experiments revealed that high-affinity TfR bispecific antibodies facilitated the trafficking of TfR

61 ath to generating highly effector-attenuated bispecific antibodies for preclinical studies.

62 These findings support the use of bispecific antibodies for the prevention or treatment of

63 Our strategy allows rapid generation of bispecific antibodies from any two existing antibodies a

64 Robust generation of IgG bispecific antibodies has been a long-standing challenge

65 Although human IgG1 bispecific antibodies have been generated, few attempts

66 Human bispecific antibodies have great potential for the treat

67 Bispecific antibodies have great potential to be the nex

68 orm conventional monoclonal antibodies, many bispecific antibodies have issues regarding production,

69 Many different formats of bispecific antibodies have meanwhile been developed.

70 Such "Trojan horse" bispecific antibodies have potential as broad antifilovi

71 nerality of the approach and show that these bispecific antibodies have properties similar to those o

72 Bispecific antibodies have therapeutic potential by expa

73 These bispecific antibodies hold promise as novel prophylactic

74 scaffolds offers the possibility to produce bispecific antibodies in vitro.

75 Comparing high- and low-affinity TfR bispecific antibodies in vivo, we found that high-affini

76 In this study, we characterized bispecific antibodies in which a BBB-crossing antibody f

77 The engineering of bispecific antibodies in which a therapeutic "arm" is co

78 g, this mechanism leads to the production of bispecific antibodies in which the LAIR1 domain is preci

79 T-cell-directed killing of tumor cells using bispecific antibodies is a promising approach for the tr

80 Using bispecific antibodies of different valencies to cell sur

81 Emerging bispecific antibodies offer the potential for even bette

82 corporation of FC5 as the BBB-carrier arm in bispecific antibodies or antibody-drug conjugates offers

83 Bispecific antibodies represent one such strategy in whi

84 Bispecific antibodies show great promise as intrinsic co

85 s and yields milligram to gram quantities of bispecific antibodies sufficient for a wide range of dis

86 Here, we report engineered bispecific antibodies that are the most potent and broad

87 gammadelta T-cell cytotoxicity, we designed bispecific antibodies that bind CD3 or Vgamma9 on gammad

88 odies that utilize a common light chain, and bispecific antibodies that pair light chains to their co

89 With this approach, we generated potent bispecific antibodies that recruit cytotoxic T lymphocyt

90 Recently, bispecific antibodies that redirect the cytotoxic activi

91 Taken together, our results show how bispecific antibodies that selectively recruit gammadelt

92 antibody constructs including one-armed Abs, bispecific antibodies that utilize a common light chain,

93 ted in the scientific literature that extend bispecific antibodies to other human antibody isotypes.

94 e, we describe a new approach for generating bispecific antibodies using a common light chain format

95 sing T-cell engaging immunotherapies such as bispecific antibodies which target T cells and tumor cel

96 des additional options for the generation of bispecific antibodies with differing effector functions

97 broadens the range of published therapeutic bispecific antibodies with natural surface architecture

98 e efficient heterodimerization, resulting in bispecific antibodies with physiochemical properties ver

99 owever, most approaches utilized to generate bispecific antibodies yield antibody-like structures tha

100 With the recent clinical success of bispecific antibodies, a strategy to rapidly synthesize

101 Fc containing therapeutics (e.g. antibodies, bispecific antibodies, and Fc fusions) requiring lack of

102 , leading to the formation of monovalent but bispecific antibodies, and it interacts poorly with Fcga

103 Chimeric proteins, including bispecific antibodies, are biological tools with therape

104 Bispecific antibodies, but not parent mAbs, neutralized

105 egies predicated on streptavidin and biotin, bispecific antibodies, complementary oligonucleotides, a

106 increasing number of multivalent antibodies, bispecific antibodies, fusion proteins, and targeted nan

107 eting" methods, particularly those utilizing bispecific antibodies, have greatly enhanced the therape

108 Bispecific antibodies, including bispecific IgG, show so

109 For bispecific antibodies, the ratio of the expression level

110 Bispecific antibodies, which simultaneously target CD3 o

111 tent antibodies and explore the potential of bispecific antibodies.

112 Using this approach, we produce 28 unique bispecific antibodies.

113 ery with possible functional implications in bispecific antibodies.

114 o 20-fold more potently than a CS1-targeting bispecific antibody (BiFab-CS1) developed in an analogou

115 inical evaluation of a recombinant AC133xCD3 bispecific antibody (bsAb) that redirects human polyclon

116 Among these, a Her2 x CD3 bispecific antibody (BsAb) was constructed by inserting

117 chimeric anticarcinoembryonic antigen (CEA) bispecific antibody (BsMAb) and peptides labeled with (1

118 To counter this problem, we developed a bispecific antibody (FIT-1) comprising ZKA190 and a seco

119 ti-diethylenetriaminepentaacetic acid (DTPA) bispecific antibody (hMN-14 x m734) (40 mg/m(2)), follow

120 The anti-FcRH5/CD3 T cell-dependent bispecific antibody (TDB) targets the B cell lineage mar

121 state cancer using an anti-TROP-2 x anti-HSG bispecific antibody (TF12) in conjunction with the dual-

122 NA to reduce antithrombin expression and the bispecific antibody ACE910/emicizumab.

123 We report a bispecific antibody against B cell maturation antigen (B

124 A bispecific antibody against the receptor tyrosine kinase

125 ased on a glycoprotein A33 (GPA33)-targeting bispecific antibody and a small-molecule radioactive hap

126 Bispecific antibody and antibody-like molecules are of w

127 Psl, and susceptibility to the anti-PcrV/Psl bispecific antibody and clinical candidate MEDI3902.

128 undergo in vivo Fab arm exchange leading to bispecific antibody and off-target effects.

129 position of the blood-brain barrier-crossing bispecific antibody antagonist of metabotropic glutamate

130 otein-coupled receptors using a BBB-crossing bispecific antibody approach and emerging principles tha

131 However, FVIII and the bispecific antibody are fundamentally different proteins

132 ignaling pathways were evaluated during EGFR bispecific antibody armed ATC (aATC)-mediated killing of

133 rm of generating bispecific IgG antibodies, "Bispecific Antibody by Protein Trans-splicing (BAPTS)".

134 he two parental antibodies and that a single bispecific antibody can neutralize 97% of viral strains

135 vel, potently neutralizing, tetravalent, and bispecific antibody composed of 2 heavy-chain-only VH (V

136 d a DropArray cell-based assay to evaluate a bispecific antibody designed to engage cytotoxic T cells

137 Catumaxomab (CatmAb), a trifunctional bispecific antibody directed against the epithelial cell

138 This bispecific antibody efficiently induces targeted cell ly

139 adionuclides, a new anti-Trop-2 x antihapten bispecific antibody for pretargeting, based on humanized

140 the construction of other disease-targeting bispecific antibody fragments for early detection and di

141 Using the DEKK format, we generated the bispecific antibody MCLA-128, targeting human EGF recept

142 A BCMA-targeted bispecific antibody presents a promising treatment optio

143 e dramatically improved therapeutic index of bispecific antibody pretargeting appears to be sufficien

144 ability, enabling efficient knobs-into-holes bispecific antibody production and a robust path to gene

145 Emicizumab is a bispecific antibody recognizing both the enzyme factor I

146 ing distinct facets of fracture healing, the bispecific antibody shows superior bone repair activity

147 port our work expanding the knobs-into-holes bispecific antibody technology to the human IgG4 isotype

148 eloid-Specific TNF Inhibitor)--a recombinant bispecific antibody that binds to the F4/80 surface mole

149 the technology with an example of a CD3/CD20 bispecific antibody that effectively depletes B cells in

150 A bispecific antibody that has two different antibody bind

151 We apply this approach to generate a bispecific antibody that targets IL-4 and IL-13, two cyt

152 Here, we engineered a bispecific antibody to detect K11/K48-linked chains and

153 As proof-of-concept, a bispecific antibody was employed as an adaptor that phys

154 ons triggered by XGFR, the Fc portion of the bispecific antibody was glycoengineered, which resulted

155 itions, resulting in a formation of a stable bispecific antibody with high yields.

156 ases bone mass, we engineer a first-in-class bispecific antibody with single residue pair mutations i

157 The bispecific antibody XGFR is based on the "knob-into-hole

158 One bispecific antibody, 10E8V2.0/iMab, neutralized 118 HIV-

159 Here, we describe the synthesis of a novel bispecific antibody, alphaCLL1-alphaCD3, using the genet

160 this study, we describe a trastuzumab-based bispecific antibody, HER2-TDB, which targets HER2 and co

161 ology to develop a heterodimeric OAscFab-IgG bispecific antibody, which combines potent signaling inh

162 , semisynthetic method for the production of bispecific antibody-like therapeutics in which a derivat

163 Abs with the potency of cytotoxic agents via bispecific antibody-toxin conjugation.

164 ed in the same cell to assemble a functional bispecific antibody.

165 nity Re-Targeting (DART) proteins, which are bispecific, antibody-based molecules that can bind 2 dis

166 However, bispecific-antibody design and production remain challen

167 Here we present a bispecific-antibody production strategy that relies on c

168 Here, we describe a bispecific-antibody strategy to target this interaction,

169 Commonly, the bispecific approach is used to achieve simultaneous cros

170 The bispecific binding modality was generated by molecular c

171 Furthermore, the bispecific binding protein successfully interferes with

172 To overcome this issue, we generated a bispecific/biparatopic antibody (BiSAb) that targets two

173 These bispecific bNAbs (BibNAbs) exploit iMab's potent anti-HI

174 We describe a novel bispecific CAR in which a CD4 segment is linked to a sin

175 ens on glioblastomas, we hypothesized that a bispecific CAR molecule would mitigate antigen escape an

176 The bispecific CD19-directed CD3 T-cell engager, blinatumoma

177 MM and non-Hodgkin lymphoma (NHL), the CD38-bispecific construct demonstrated excellent blood cleara

178 The bispecific constructs were all able to bind both target

179 bispecific variants, but not their bivalent bispecific counterparts, mediated a greater degree of tu

180 roved with the adjuvant use of a VEGF-A/Ang2-bispecific CovX-body (CVX-241) but not when CVX-060 is c

181 ur results demonstrate that antiCD3/antiCD22 bispecific CSANs offer a potential alternative to CARs,

182 The described bispecific DARPin protein has the ability to co-ligate F

183 (Hc) heterodimers represent a major class of bispecific drug candidates.

184 -MET with potentially broad implications for bispecific drug efficacy and design.

185 ctivity, and therapeutic capacity of a novel bispecific dual-affinity retargeting molecule (DART) tha

186 Systemic administration of the bispecific DVD-Ig or the TGF-beta mAb (1-10 mg/kg) but n

187 Affinity-attenuated bispecific EGFR x c-MET antibody-drug conjugates demonst

188 We engineered a bispecific EGFR-cMet antibody (JNJ-61186372) with multip

189 l antibodies and combined them into a single bispecific Fc fusion protein (the Fc dual-affinity retar

190 anti-H5N1 influenza virus antibodies into a bispecific FcDART molecule, which represents a strategy

191 We demonstrate that the multivalent and bispecific format allows the antiCD3/antiCD22 CSANs to s

192 Here, we present a bispecific format where we have fused two full-sized IgG

193 properties over two established tetravalent bispecific formats.

194 ribution experiments comparing SA-biotin and bispecific FP (2H7-Fc-C825) PRIT in murine subjects bear

195 In this study, we engineered a bispecific fusion protein (FP) that evades the limitatio

196 Intriguingly, treatment with the bispecific fusion protein also directed early T cell dif

197 To promote this event, a bispecific fusion protein comprising a mutant mouse CD80

198 Treating T cells with this bispecific fusion protein inhibited T cell activation.

199 nancies, for which we developed an anti-CD38-bispecific fusion protein that eliminates endogenous bio

200 Thus, bispecific fusion proteins that engage CTLA-4 and co-lig

201 th sugar, suggesting that 11D wcrL encodes a bispecific glycosyltransferase.

202 imer under different storage conditions, the bispecific heterodimer, guided by the knob-into-hole ass

203 to increases in both rate and efficiency of bispecific (heterodimer) assembly.

204 ine the affinity of parental (homodimer) and bispecific (heterodimer) interactions within the CH3 dom

205 escribe a new strategy for making monovalent bispecific heterodimeric IgG antibodies in mammalian cel

206 In addition, the bispecific heterodimeric IgG derived from anti-HER2 and

207 enhancement could be embedded in monovalent bispecific heterodimeric IgG to make best-in-class thera

208 The bispecific HexAbs have different properties from and are

209 minimal point mutations, to form full-length bispecific human antibodies with high efficiency and in

210 novel one-arm single chain Fab heterodimeric bispecific IgG (OAscFab-IgG) antibody format targeting t

211 This bispecific IgG also demonstrated in vivo pharmacokinetic

212 a generic technology platform of generating bispecific IgG antibodies, "Bispecific Antibody by Prote

213 heavy chain pairing variants in a mixture of bispecific IgG assembled in vivo upon coexpression down

214 Generating bispecific IgG by coexpression of two different light an

215 Bispecific IgG can be made by separate expression and pu

216 We developed four different bispecific IgG variants that included antibodies targeti

217 contribution of doubly light chain mispaired bispecific IgG was demonstrated.

218 n simultaneously co-expressed, assemble into bispecific IgG with improved heavy chain-light chain pai

219 Using an anti-IL-4/IL-13 bispecific IgG, a mass spectrometric characterization me

220 Bispecific antibodies, including bispecific IgG, show some promise in clinical trials as

221 -cell solution for streamlined production of bispecific IgG.

222 aired IgG species in addition to the desired bispecific IgG.

223 nt human IgG clones, including a non-natural bispecific IgG1 candidate, targeting Pseudomonas aerugin

224 fically, a series of monovalent and bivalent bispecific IgGs composed of the anti-HER2 trastuzumab mo

225 We show that these bispecific IgGs display features of both antibody specif

226 Bispecific IgGs generated with this approach exhibit pha

227 All four bispecific IgGs neutralized 94% to 97% of antigenically

228 Among the bispecific IgGs tested, VRC07 x PG9-16 displayed the mos

229 Herein, we generated a bispecific immunoconjugate [denoted as Bs-F(ab)2] by lin

230 In this study, we constructed bispecific immunoglobulins (IgGs) composed of independen

231 ed constructs (including Fab, Fc-fusions and bispecifics) in mammalian cells.

232 erefore, we evaluated an antibody-engineered bispecific inhibitor against TAFI and PAI-1 (heterodimer

233 In conclusion, administration of a bispecific inhibitor against TAFI and PAI-1 results in a

234 G-1 orthologs homodimerize through a common, bispecific interface that similarly mediates an unusual

235 ontrols, suggesting target engagement of TfR bispecific is not limited.

236 Blood and marrow MDS-NK cells treated with bispecific killer cell engager (BiKE) significantly enha

237 Bispecific killer cells engagers (BiKEs) which can bind

238 A bispecific mAb targeting both Psl and PcrV enhanced neut

239 inders against FcgammaRIIB and to generate a bispecific molecule simultaneously targeting FcgammaRIIB

240 Overall, systemic delivery of a bispecific molecule targeting an extracellular matrix pr

241 anding of both the homodimer variant and the bispecific molecule.

242 rated into a comprehensive panel of distinct bispecific molecules by controlled Fab-arm exchange (Duo

243 Proteolysis targeting chimeras (PROTACs) are bispecific molecules containing a target protein binder

244 Further, we found that an Fc-modified, bispecific monoclonal antibody against conserved epitope

245 Blinatumomab, a bispecific monoclonal antibody construct that enables CD

246 PRIT of CEA-expressing xenografts, using the bispecific monoclonal antibody TF2 (anti-CEA x anti-hist

247 utralizing potency and breadth, we generated bispecific multivalent fusion proteins of mD1.22 with an

248 Evolution from an NADP(+) to a bispecific NADP(+) and CoA binding site involves many am

249 strategy to rapidly synthesize and evaluate bispecific or higher order multispecific molecules could

250 whereas at 600- and 1000-microCi doses, the bispecific outperformed the SA approach, curing 35% more

251 y half of the circulating IgG4 molecules are bispecific owing to their unique ability to exchange hal

252 al proof of concept for the preferred use of bispecific PRIT in future clinical trials, due to a slig

253 In therapy studies, CD38-bispecific PRIT resulted in 100% complete remissions by

254 The high efficacy of bispecific PRIT, combined with its reduced risk of immun

255 nd/or diagnostic agents that can bind to the bispecific proteins accumulated on the surface of target

256 lving the administration of 1) a cocktail of bispecific proteins that can collectively bind to the en

257 In direct comparisons, efficacy of the CD38 bispecific proved equal or superior to streptavidin (SA)

258 We have developed (111)In-labeled bispecific radioimmunoconjugates (bsRICs) that bind HER2

259 Our objective was to construct bispecific radioimmunoconjugates (bsRICs) that recognize

260 As such, these bispecific reagents may be useful in many biotechnologic

261 tool for generating sandwich ELISA-grade and bispecific reagents.

262 ABARAP, GABL1, GABL2, and LC3C, as well as a bispecific sensor for LC3A and LC3B.

263 he pan-HDAC inhibitor, vorinostat, to create bispecific single molecules with both JAK and HDAC targe

264 to the C terminus of a single-chain Fv and a bispecific single-chain diabody, respectively.

265 A bispecific, single variable-domain antibody (anti-TNFRI

266 t surface antigens pretreated with different bispecific streptavidin-scFv fusion proteins.

267 AMG 110, a bispecific T cell engager (BiTE) antibody construct, ind

268 In this study, a bispecific T cell engager (BiTE) approach was used to di

269 evaluate tumor and tissue uptake kinetics of bispecific T cell engager antibody constructs in preclin

270 Here, we evaluated the CD33/CD3-bispecific T cell engaging (BiTE) antibody (AMG 330) for

271 L and can be targeted by the investigational bispecific T cell-engager antibody blinatumomab.

272 Bispecific T-cell engager (BiTE((R))) antibody construct

273 Here we describe a bispecific T-cell engager (BiTE) antibody derived from a

274 L relapses after treatment with the CD19/CD3 bispecific T-cell engager (BiTE) blinatumomab.

275 tibodies (bscAbs), particularly those of the bispecific T-cell engager (BiTE) subclass, have been sho

276 ree survival (RFS) in a phase 2 study of the bispecific T-cell engager antibody construct blinatumoma

277 Blinatumomab is a bispecific T-cell engager antibody construct targeting C

278 Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting C

279 the activity of the novel CD33/CD3-directed bispecific T-cell engager antibody, AMG 330.

280 Among these, the bispecific T-cell engager blinatumomab has emerged as th

281 The bispecific T-cell engager blinatumomab targeting CD19 ca

282 Blinatumomab is a CD19/CD3 BiTE (bispecific T-cell engager) antibody construct for the tr

283 antigen receptors (CARs) or the infusion of bispecific T-cell engagers (BITEs) have shown antitumor

284 (ii) engineered monoclonal antibodies called bispecific T-cell engagers; (iii) monoclonal antibodies

285 Blinatumomab, a bispecific T-cell engaging antibody construct, transient

286 Blinatumomab is a CD19/CD3-bispecific T-cell receptor-engaging (BiTE) antibody with

287 oncolytic adenoviruses that were armed with bispecific T-cell-engager (BiTE) antibodies.

288 ostat (2), leading to new molecules that are bispecific targeted JAK/HDAC inhibitors.

289 netics, and safety of a CD3 T cell-dependent bispecific (TDB) full-length human IgG1 therapeutic anti

290 Current state-of-the-art human IgG-like bispecific technologies require co-expression of two hea

291 AFM13 is a bispecific, tetravalent chimeric antibody construct (Tan

292 ize TGF-beta After systemic injection of the bispecific TGF-beta + FnEDA DVD-Ig or an FnEDA mAb, chem

293 roteins are key potential building blocks of bispecific therapeutic antibodies, but they often suffer

294 In this study, we have generated bispecific therapeutic fusion proteins in mammalian cell

295 postproduction method for the generation of bispecific therapeutic IgGs of which several have progre

296 erlooked when developing clinically relevant bispecific therapeutics.

297 Affinity-reduced monovalent bispecific variants, but not their bivalent bispecific c

298 antibodies (anti-transferrin receptor [TfR] bispecific versus control antibody) in mouse models of A

299 ver, the mechanisms by which these so-called bispecific VHH heterodimers promote toxin neutralization

300 Finally, a bispecific VNA (VHH-based neutralizing agent) consisting